BioSeek and UCB sign collaboration agreement

Under the collaboration, BioSeek will apply its BioMAP Systems to evaluate a number of UCB compounds across several target classes, in support of target differentiation, lead development, and drug candidate selection activities at UCB.

BioSeek’s BioMAP systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. BioSeek is using BioMAP Systems for primary screening, to rapidly generate lead compounds that have novel activity in a particular disease setting.

Michael Venuti, CEO of BioSeek, said: “This collaboration leverages the power of our systems biology technology across multiple disease areas and multiple phases of the drug development process.”